BidaskClub upgraded shares of Novartis AG (NYSE:NVS) from a sell rating to a hold rating in a research report released on Saturday.

A number of other research analysts have also commented on the company. TheStreet raised Novartis AG from a c+ rating to a b rating in a report on Friday, June 2nd. Barclays PLC raised Novartis AG from an underweight rating to an equal weight rating in a report on Thursday, June 22nd. Zacks Investment Research raised Novartis AG from a strong sell rating to a hold rating in a report on Monday, May 1st. Vetr lowered Novartis AG from a buy rating to a hold rating and set a $78.32 price target on the stock. in a report on Tuesday, April 25th. Finally, Cowen and Company set a $77.00 price target on Novartis AG and gave the company a hold rating in a report on Tuesday, July 11th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $81.71.

Novartis AG (NYSE:NVS) opened at 84.16 on Friday. The stock has a market capitalization of $197.18 billion, a price-to-earnings ratio of 30.73 and a beta of 0.73. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90. The company has a 50-day moving average of $83.98 and a 200-day moving average of $78.22.

Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. During the same period last year, the company earned $1.23 earnings per share. The firm’s revenue for the quarter was down 1.8% on a year-over-year basis. Equities research analysts expect that Novartis AG will post $4.75 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/09/novartis-ag-nvs-upgraded-by-bidaskclub-to-hold.html.

In other news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,000,005.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.01% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in NVS. Howe & Rusling Inc. boosted its position in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock valued at $100,000 after buying an additional 882 shares in the last quarter. City Holding Co. boosted its position in shares of Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after buying an additional 54 shares in the last quarter. TCI Wealth Advisors Inc. boosted its position in shares of Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock valued at $103,000 after buying an additional 230 shares in the last quarter. Archford Capital Strategies LLC boosted its position in shares of Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after buying an additional 621 shares in the last quarter. Finally, Kernodle & Katon Asset Management Group LLC boosted its position in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares in the last quarter. 11.27% of the stock is owned by institutional investors and hedge funds.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.